| Abstrakt: |
A study conducted by researchers at Nankai University in Tianjin, China, has found that vitamin D-binding protein (VDBP) inhibits vasculogenic mimicry (VM) in hepatocellular carcinoma (HCC), a type of liver cancer. The study suggests that VDBP expression is negatively correlated with VM in HCC patients and that elevated VDBP expression is associated with a favorable prognosis. The researchers also discovered that combining vitamin D (VD) with an anti-PD-1 drug improved the anti-tumor efficacy of the drug. This research identifies VDBP as a potential prognostic biomarker and therapeutic target for HCC patients. [Extracted from the article] |
